NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients

Li,Xiaoyu; Guo,Fuchun; Liu,Yongmei; Chen,Hui‑Jiao; Wen,Feng; Zou,Binwen; Li,Dan; Qin,Qin; Liu,Xiaoke; Shen,Yali; Wang,Yongsheng

doi:10.3892/ol.2015.3471

NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients

Authors:
- Xiaoyu Li
- Fuchun Guo
- Yongmei Liu
- Hui‑Jiao Chen
- Feng Wen
- Binwen Zou
- Dan Li
- Qin Qin
- Xiaoke Liu
- Yali Shen
- Yongsheng Wang
View Affiliations

Affiliations: Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Abdomen Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: July 8, 2015 https://doi.org/10.3892/ol.2015.3471
Pages: 1533-1540

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Major histocompatibility complex (MHC) class I molecules have a crucial role in tumor immune evasion; however, the association of MHC class I molecules with outcomes in cancer patients remains controversial. Nucleotide‑binding oligomerization‑like receptor family caspase recruitment domain‑containing 5 (NLRC5) has been reported to be a MHC class I transactivator. However, the expression and function of NLRC5 in cancer remains to be elucidated. The present study aimed to retrospectively examine NLRC5 expression in human tumor tissues and its association with clinical outcomes of non‑small‑cell lung cancer (NSCLC) stage III patients. The expression of MHC class I and NLRC5 in NSCLC were detected using immunohistochemistry (IHC). The association between their expression levels was assessed using the Pearson's χ2 test and their association with survival was assessed using Kaplan‑Meier analysis and the log‑rank test. In addition, the expression of NLRC5 and MHC class I were examined in 323 cases of seven other types of tumors and their correlations were studied. The results revealed that the expression of NLRC5 was correlated with that of MHC class I in NSCLC patients (P=0.008). MHC class I‑positive and nuclear NLRC5‑positive NSCLC patients were found to have shorter overall survival (OS) rates (log‑rank, P=0.032 and P=0.039, respectively). In addition, in the seven different tumor types, there was a significant correlation between MHC class I and NLRC5 nuclear expression (P<0.001) as well as MHC class I and NLRC5 cytoplasmic expression (P=0.003). In conclusion, NLRC5 was demonstrated to be widely expressed in eight tumor tissues and its expression was correlated with that of MHC class I. Of note, nuclear NLRC5‑negative and MHC class I‑negative stage III NSCLC patients had improved OS rates compared to those with positive expression. Therefore, NLRC5 and MHC class I may be negative prognostic indicators in NSCLC stage III patients.

View Figures

View References

1	Igney FH and Krammer PH: Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol. 71:907–920. 2002.PubMed/NCBI
2	Garcia-Lora A, Algarra I and Garrido F: MHC class I antigens, immune surveillance and tumor immune escape. J Cell Physiol. 195:346–355. 2003. View Article : Google Scholar : PubMed/NCBI
3	Garrido F, Cabrera T, Concha A, et al: Natural history of HLA expression during tumour development. Immunol Today. 14:491–499. 1993. View Article : Google Scholar : PubMed/NCBI
4	Kärre K: NK cells, MHC class I molecules and the missing self. Scand J Immunol. 55:221–228. 2002. View Article : Google Scholar : PubMed/NCBI
5	Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M and Durrant LG: Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut. 59:926–933. 2010. View Article : Google Scholar : PubMed/NCBI
6	Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ and Garrido F: MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer. 106:521–527. 2003. View Article : Google Scholar : PubMed/NCBI
7	Madjd Z, Spendlove I, Pinder SE, Ellis IO and Durrant LG: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 117:248–255. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ramnath N, Tan D, Li Q, et al: Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother. 55:891–899. 2006. View Article : Google Scholar : PubMed/NCBI
9	Meissner TB, Li A, Liu YJ, Gagnon E and Kobayashi KS: The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity. Biochem Biophys Res Commun. 418:786–791. 2012. View Article : Google Scholar : PubMed/NCBI
10	Staehli F, Ludigs K, Heinz LX, et al: NLRC5 deficiency selectively impairs MHC Class I- dependent lymphocyte killing by cytotoxic T cells. J Immunol. 188:3820–3828. 2012. View Article : Google Scholar : PubMed/NCBI
11	Magalhaes JG, Sorbara MT, Girardin SE and Philpott DJ: What is new with Nods? Curr Opin Immunol. 23:29–34. 2011. View Article : Google Scholar : PubMed/NCBI
12	Barker BR, Taxman DJ and Ting JP: Cross-regulation between the IL-1β/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol. 23:591–597. 2011. View Article : Google Scholar : PubMed/NCBI
13	Benko S, Magalhaes JG, Philpott DJ and Girardin SE: NLRC5 limits the activation of inflammatory pathways. J Immunol. 185:1681–1691. 2010. View Article : Google Scholar : PubMed/NCBI
14	Davis BK, Roberts RA, Huang MT, et al: Cutting Edge: NLRC5-dependent activation of the inflammasome. J Immunol. 186:1333–1337. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cui J, Zhu L, Xia X, et al: NLRC5 negatively regulates the NF-κB and type I interferon signaling pathways. Cell. 141:483–496. 2010. View Article : Google Scholar : PubMed/NCBI
16	Neerincx A, Lautz K, Menning M, et al: A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses. J Biol Chem. 285:26223–26232. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yao Y and Qian Y: Expression regulation and function of NLRC5. Protein Cell. 4:168–175. 2013. View Article : Google Scholar : PubMed/NCBI
18	Biswas A, Meissner TB, Kawai T and Kobayashi KS: Cutting edge: Impaired MHC class I expression in mice deficient for Nlrc5/Class I transactivator. J Immunol. 189:516–520. 2012. View Article : Google Scholar : PubMed/NCBI
19	Brambilla E, Travis WD, Colby TV, et al: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
20	Fan L, Li P, Yin Z, et al: Ribosomal s6 protein kinase 4: A prognostic factor for renal cell carcinoma. Br J Cancer. 109:1137–1146. 2013. View Article : Google Scholar : PubMed/NCBI
21	Rimsza LM, Roberts RA, Miller TP, et al: Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 103:4251–4258. 2004. View Article : Google Scholar : PubMed/NCBI
22	Bijen CB, Bantema-Joppe EJ, de Jong RA, et al: The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 126:1417–1427. 2010.PubMed/NCBI
23	Hicklin DJ, Marincola FM and Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today. 5:178–186. 1999. View Article : Google Scholar : PubMed/NCBI
24	Dunn GP, Old LJ and Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360. 2004. View Article : Google Scholar : PubMed/NCBI
25	Nagata Y, Hanagiri T, Mizukami M, et al: Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer. 65:91–97. 2009. View Article : Google Scholar : PubMed/NCBI
26	Nijman HW, van Diest PJ, Poort-Keesom RJ, et al: T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 94:114–120. 2001. View Article : Google Scholar : PubMed/NCBI
27	Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ and Meijer CJ: Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer. 69:1176–1181. 1994. View Article : Google Scholar : PubMed/NCBI
28	Cromme FV, Meijer CJ, Snijders PJ, Uyterlinde A, Kenemans P, Helmerhorst T, Stern PL, van den Brule AJ and Walboomers JM: Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer. 67:1372–1380. 1993. View Article : Google Scholar : PubMed/NCBI
29	Atkins D, Ferrone S, Schmahl GE, Störkel S and Seliger B: Down-regulation of HLA class I antigen processing molecules: An immune escape mechanism of renal cell carcinoma? J Urol. 171:885–889. 2004. View Article : Google Scholar : PubMed/NCBI
30	Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI
31	Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, Iliopoulos D, van den Elsen PJ and Kobayashi KS: NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA. 107:13794–13799. 2010. View Article : Google Scholar : PubMed/NCBI
32	Meissner TB, Liu YJ, Lee KH, Li A, Biswas A, van Eggermond MC, van den Elsen PJ and Kobayashi KS: NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression. J Immunol. 188:4951–4958. 2012. View Article : Google Scholar : PubMed/NCBI